Phenotypic Clustering of Beta-Thalassemia Intermedia Patients Using Cardiovascular Magnetic Resonance
Authors:
- Antonella MeloniAntonella Meloni
- Michela ParravanoMPMichela Parravano
- Laura PistoiaLaura Pistoia
- Alberto CossuACAlberto Cossu
- Emanuele GrassedonioEGEmanuele Grassedonio
- Stefania RenneSRStefania Renne
- Priscilla FinaPFPriscilla Fina
- Anna SpasianoASAnna Spasiano
- Alessandra SalvoASAlessandra Salvo
- Sergio BagnatoSBSergio Bagnato
- Calogera GerardiCGCalogera Gerardi
- Zelia BorsellinoZBZelia Borsellino
Open Access
- 24 October 2023
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (21) , 6706
Abstract
We employed an unsupervised clustering method that integrated demographic, clinical, and cardiac magnetic resonance (CMR) data to identify distinct phenogroups (PGs) of patients with beta-thalassemia intermedia (β-TI). We considered 138 β-TI patients consecutively enrolled in the Myocardial Iron Overload in Thalassemia (MIOT) Network who underwent MR for the quantification of hepatic and cardiac iron overload (T2* technique), the assessment of biventricular size and function and atrial dimensions (cine images), and the detection of replacement myocardial fibrosis (late gadolinium enhancement technique). Three mutually exclusive phenogroups were identified based on unsupervised hierarchical clustering of principal components: PG1, women; PG2, patients with replacement myocardial fibrosis, increased biventricular volumes and masses, and lower left ventricular ejection fraction; and PG3, men without replacement myocardial fibrosis, but with increased biventricular volumes and masses and lower left ventricular ejection fraction. The hematochemical parameters and the hepatic and cardiac iron levels did not contribute to the PG definition. PG2 exhibited a significantly higher risk of future cardiovascular events (heart failure, arrhythmias, and pulmonary hypertension) than PG1 (hazard ratio-HR = 10.5; p = 0.027) and PG3 (HR = 9.0; p = 0.038). Clustering emerged as a useful tool for risk stratification in TI, enabling the identification of three phenogroups with distinct clinical and prognostic characteristics.Keywords
Funding Information
- Chiesi Farmaceutici S.p.A.
- ApoPharma Inc.
This publication has 72 references indexed in Scilit:
- Cardiovascular Function and Treatment in β-Thalassemia MajorCirculation, 2013
- Role of hepcidin in the pathophysiology and diagnosis of anemiaBlood Research, 2013
- β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolismBlood, 2011
- Hepcidin regulates ferroportin expression and intracellular iron homeostasis of erythroblastsBlood, 2011
- Beta-thalassemiaOrphanet Journal of Rare Diseases, 2010
- Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion‐independent thalassemia intermedia compared to regularly transfused thalassemia major patientsAmerican Journal of Hematology, 2009
- CARDIAC FUNCTION AND IRON CHELATION IN THALASSEMIA MAJOR AND INTERMEDIA: A REVIEW OF THE UNDERLYING PATHOPHYSIOLOGY AND APPROACH TO CHELATION MANAGEMENTMediterranean Journal of Hematology and Infectious Diseases, 2009
- Late Gadolinium Enhancement by Cardiovascular Magnetic Resonance Heralds an Adverse Prognosis in Nonischemic CardiomyopathyJACC, 2008
- Magnetic Resonance Imaging Assessment of Excess Iron in Thalassemia, Sickle Cell Disease and Other Iron Overload DiseasesHemoglobin, 2008
- Diagnosis and management of transfusion iron overload: The role of imagingAmerican Journal of Hematology, 2007